The estimated Net Worth of Junge Zhang is at least $6.29 Milione dollars as of 14 June 2023. Mr. Zhang owns over 200,278 units of Ocugen Inc stock worth over $1,324,934 and over the last 5 years he sold OCGN stock worth over $4,960,971. In addition, he makes $0 as Independent Director at Ocugen Inc.
Junge has made over 10 trades of the Ocugen Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 200,278 units of OCGN stock worth $100,139 on 14 June 2023.
The largest trade he's ever made was buying 270,000 units of Ocugen Inc stock on 27 November 2019 worth over $99,900. On average, Junge trades about 82,844 units every 80 days since 2019. As of 14 June 2023 he still owns at least 1,077,182 units of Ocugen Inc stock.
You can see the complete history of Mr. Zhang stock trades at the bottom of the page.
Junge Zhang Ph.D. serves as Independent Director of the Company. Dr. Zhang has served as a member of the board of directors of OpCo, our wholly owned subsidiary, since May 2015. Dr. Zhang has served as the Founder, President, and CEO of Biopeptek Pharmaceuticals LLC, a custom peptide manufacturing company, since its founding in October 2010. Prior to founding Biopeptek, Dr. Zhang was with the Janssen Pharmaceutical division of Johnson & Johnson from October 2002 to April 2011. Before joining Johnson & Johnson, Dr. Zhang was a Senior Chemist at Eisai USA from December 1997 to October 2002. Dr. Zhang earned a Ph.D. in analytical chemistry from Drexel University, an M.S. in chemistry from University of Louisiana, and a B.S. in material science from Wuhan University of Technology in China. Our Board believes Dr. Zhang’s extensive senior management experience in the pharmaceutical industry provides him with the qualifications and skills to serve on our Board.
Junge Zhang is 53, he's been the Independent Director of Ocugen Inc since 2019. There are 10 older and 6 younger executives at Ocugen Inc. The oldest executive at Ocugen Inc is Prabhavathi Fernandes, 71, who is the Independent Director.
Junge's mailing address filed with the SEC is C/O OCUGEN, INC., 11 GREAT VALLEY PARKWAY, MALVERN, PA, 19355.
Over the last 5 years, insiders at Ocugen Inc have traded over $18,069,176 worth of Ocugen Inc stock and bought 1,511,356 units worth $684,830 . The most active insiders traders include Shankar Musunuri, Junge Zhang e Uday Kompella. On average, Ocugen Inc executives and independent directors trade stock every 21 days with the average trade being worth of $96,347. The most recent stock trade was executed by Junge Zhang on 14 June 2023, trading 200,278 units of OCGN stock currently worth $100,139.
ocugen, inc., is a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved ocular disorders. the company’s lead programs in ocular graft versus host disease (ocu300) and chronic dry eye disease (ocu310) are expected to enter pivotal clinical trials in 2018. ocu300 received the first and only orphan drug designation for ocular graft versus host disease, providing certain regulatory and economic benefits. ocugen is also developing novel biologic therapies for retinitis pigmentosa (ocu100) and wet amd (ocu200), as well as a groundbreaking modifier gene therapy platform with potential to address a broad spectrum of inherited retinal disorders (ocu400). for more information, please visit www.ocugen.com.
Ocugen Inc executives and other stock owners filed with the SEC include: